All News
Examples from the world of dermatology on JAK inhibitor success stories.
Bruce storber.
#RNL2024
@RheumNow https://t.co/S01lEIqjbR
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases.
Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓
Bruce Strober
#RNL2024
@RheumNow https://t.co/2yHHcOgTC8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Allosteric versus active site inhibition by JAK.
Never understood this better.
Thanks to Bruce Strober.
#RNL2024
@RheumNow https://t.co/r9hhHLO5oS
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAK safety and malignancy risk.
Great talk by kevin Winthrop.
#RNL2024
@RheumNow https://t.co/d7WRHJxrpM
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@BharatKumarMD at #RNL2024 @RheumNow
Appreciative Inquiry in Rheumatology
5(ish) steps
Dawn (what focus on) -> Discovery (what gives life) -> Dream (what might be) -> Design (what should be) -> Destiny (how can i execute) -> New Dawn
- Empathy at center of inquiry https://t.co/gDhXpi94pT
Eric Dein ericdeinmd ( View Tweet)
JAK toxicity of interest.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Unique and selective allosteric mechanism of deucravacitinib.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/Zm3bYGR9JJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Disease activity indices may perform differently in man and women.
@lihi_eder
#RNL2024
@RheumNow https://t.co/8G1D0pGKe8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Diagnostic delay in SpA
2.3 years longer delay in diagnosis in women with PsA.
@lihi_eder
#RNL2024
@RheumNow https://t.co/d9ao8vvpa5
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
I am jealous of the derms who have topical JAKi!
Dr. Strober flaunts all the different JAKi he has at his disposal to treat derm diseases #RNL2024 @rheumnow https://t.co/qdMWCSA5I1
TheDaoIndex KDAO2011 ( View Tweet)
JAK and TYK2 signaling pathways.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/WxoZGCEL0z
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAKinib negatives.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/vVzSQMVa5a
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
"Any vacuolar interface dermatitis will respond to a JAKi" - Dr. B Strober noted JAKi will work for cutaneous lupus #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Have you seen tachyphylaxis in JAKi? #RNL2024 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Winthrop avoid JAKi and TNFi in pts with chronic lung infections like MAI. #RNL2024 @rheumnow https://t.co/TfMa7hktL9
TheDaoIndex KDAO2011 ( View Tweet)
Dr. B Strober emphasizes that #AtopicDermatitis is not just found in children. A large proportion of patients are over 50 years of age when they are diagnosed. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Do you check CPK on patients who are on JAK inhibitors? #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
For pts on JAKi needing vaccines; to avoid diminishing vaccine efficacy, Dr. Winthrop noted he treats a JAKi like he would MTX in that he holds the JAKi a week after vaccinating. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl!
Dr. Winthrop holds JAKi for one week after vaccination.
#RNL2024 @RheumNow https://t.co/BLiKu8xX7t
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Strober's JAKi in dermatology takeaways!
- Consider this for AD
- Dose matters in terms of both efficacy and toxicity
- Consider combination tx
- Topical JAKi option for vitiligo, especially head and neck involvement (harder in hands and other areas)
#RNL2024 @RheumNow https://t.co/ZrPfpUF4Hz
Dr. Rachel Tate uptoTate ( View Tweet)